Long Brit, Koyfman Alex
Department of Emergency Medicine, San Antonio Military Medical Center, Fort Sam Houston.
Department of Emergency Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.
J Emerg Med. 2017 May;52(5):668-679. doi: 10.1016/j.jemermed.2016.11.020. Epub 2016 Dec 19.
Pulmonary embolism (PE) is a common condition managed in the emergency department (ED), with a wide range of morbidity and mortality. Patients are classically admitted for treatment and monitoring of anticoagulation.
We sought to evaluate the controversy concerning outpatient therapy for patients with acute PE and investigate the feasibility, safety, and efficacy of outpatient management.
Patients with venous thromboembolism have historically been admitted for treatment and monitoring for concern of worsening disease or side effects of anticoagulation (bleeding). More than 90% of EDs admit patients with PE in the United States. However, close to 50% of patients may be appropriate for discharge and outpatient therapy. The published literature suggests that outpatient treatment is safe, feasible, and efficacious, with similar rates of recurrent venous thromboembolism and all-cause mortality, especially with novel oral anticoagulants. Multiple scoring criteria can be used, including the Pulmonary Embolism Severity Index (PESI), simplified PESI, Hestia criteria, Geneva Prognostic Score, European Society of Cardiology guidelines, Global Registry of Acute Coronary Events, and Aujesky score. Simplified PESI and the European Society of Cardiology guidelines have high-quality evidence, sufficient sensitivity, and ease of use for the ED. Patients considered for outpatient therapy should possess low hemorrhage risk, adequate social situation, negative biomarkers, ability to comply, and no alternate need for admission.
Patients with acute PE are often admitted in the United States, but a significant proportion may be appropriate for discharge. Patients with low risk for adverse events according to clinical scoring criteria, adequate follow-up, ability to comply, and no other need for admission can be discharged with novel oral anticoagulant therapy.
肺栓塞(PE)是急诊科(ED)常见的病症,其发病率和死亡率范围广泛。传统上,患者会住院接受抗凝治疗和监测。
我们旨在评估急性PE患者门诊治疗的争议,并调查门诊管理的可行性、安全性和有效性。
历史上,静脉血栓栓塞患者因担心病情恶化或抗凝治疗的副作用(出血)而住院接受治疗和监测。在美国,超过90%的急诊科会收治PE患者。然而,近50%的患者可能适合出院和门诊治疗。已发表的文献表明,门诊治疗是安全、可行且有效的,复发性静脉血栓栓塞和全因死亡率相似,尤其是使用新型口服抗凝剂时。可使用多种评分标准,包括肺栓塞严重程度指数(PESI)、简化PESI、赫斯提亚标准、日内瓦预后评分、欧洲心脏病学会指南、急性冠状动脉事件全球注册研究和奥耶斯基评分。简化PESI和欧洲心脏病学会指南有高质量证据,敏感性足够,且便于急诊科使用。考虑门诊治疗的患者应具有低出血风险、适当的社会状况、阴性生物标志物、依从能力且无其他住院需求。
在美国,急性PE患者通常会住院,但很大一部分患者可能适合出院。根据临床评分标准,不良事件风险低、随访充分、有依从能力且无其他住院需求的患者可以接受新型口服抗凝剂治疗后出院。